Evidence map›Paper›PMID 37433686›Full record

ArticleBMJ case reports2023

Concurrent NMDAR and GFAP Antibody Encephalitis During Pregnancy.

Erkam Zengin, Irina Kharisova, Dokpe Emechebe, Yaacov Anziska

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Erkam ZenginNeurology Department, SUNY Downstate Health Sciences University, Brooklyn, New York, USA erkam.zengin@downstate.edu.ORCID http://orcid.org/0000-0002-8213-2845
Irina KharisovaNeurology Department, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Dokpe EmechebePathology Department, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Yaacov AnziskaNeurology Department, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
SUNY Downstate Health Sciences University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune antibody encephalitis, commonly affecting young women with comorbid ovarian teratoma. It typically presents with alteration of consciousness, psychosis, movement disorders eventually deteriorating with seizures, dysautonomia and central hypoventilation requiring critical level of care that may last weeks to months. Removal of teratoma and immunosuppressant therapy support can led to a dramatic recovery.To our knowledge, this is the first illustrated case in the literature of a pregnant woman presenting with concurrent autoimmune NMDAR and anti-glial gibrillary acidic protein(GFAP) antibody encephalitis in the setting of an ovarian teratoma. Despite the teratoma removal and receiving various forms of immunosuppressant therapy, a meaningful neurological improvement was observed following the delivery. After a prolonged hospitalisation and recovery period, the patient and her offspring made an excellent recovery highlighting the significance of early diagnosis and management.

Indexed as

Anti-N-Methyl-D-Aspartate Receptor EncephalitisReceptors, Amino AcidAutoantibodiesEncephalitisFemaleHashimoto DiseaseHumansImmunosuppressive AgentsOvarian NeoplasmsPregnancyTeratomaaspartic acid receptorAutoantibodiesImmunosuppressive AgentsReceptors, Amino AcidImmunologyNeonatal healthNeurologyPsychiatry

Identifiers

PMID37433686
PMCPMC10347501
OpenAlexW4383874311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.